Expansion of Fields Planned After Designation of GLP Institutions for Veterinary Pharmaceuticals and Others
Gyeongbuk Technopark Medical Convergence Materials Commercialization Center located within the Gyeongbuk Knowledge Industry District.
[Asia Economy Yeongnam Reporting Headquarters Reporter Yeo Jong-gu] The Medical Convergence Materials Commercialization Center at Gyeongbuk Technopark was designated as a non-clinical trial institution for medical devices by the Ministry of Food and Drug Safety on the 4th.
A non-clinical trial institution (GLP) is an organization that operates all related matters such as research personnel, experimental facilities, equipment, and test methods according to regulations to guarantee reliability in fields requiring safety evaluation of pharmaceuticals, cosmetics, and medical devices.
Since May 2019, the Ministry of Food and Drug Safety has been implementing the medical device GLP system to ensure the safety and reliability of medical devices.
The Medical Convergence Materials Commercialization Center was established in the Gyeongsan Knowledge Industry District with support from the Ministry of Trade, Industry and Energy, Gyeongbuk Province, and Gyeongsan City, aiming to support companies in the medical materials industry sector.
This designation as a trial institution supports local bio, medical, and chemical material companies through research support in medical materials, pharmaceuticals, and chemical substances, as well as projects such as the bio-cosmetic ecosystem creation project and the Gyeongbuk precision chemical materials industry competitiveness enhancement support project.
Furthermore, this year, the certification scope in the medical device field will be expanded to strengthen the technological competitiveness of the local bio and medical materials industry.
Ha In-seong, President of Gyeongbuk Technopark, stated, “As a GLP institution in Gyeongbuk with high expertise and reliability, we will do our best to attract related companies and foster the industry so that local companies can proactively respond to paradigm shifts in the medical device industry.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

